TY - JOUR
T1 - Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults
AU - Saeed, Anum
AU - Nambi, Vijay
AU - Sun, Wensheng
AU - Virani, Salim S.
AU - Taffet, George E.
AU - Deswal, Anita
AU - Selvin, Elizabeth
AU - Matsushita, Kunihiro
AU - Wagenknecht, Lynne E.
AU - Hoogeveen, Ron
AU - Coresh, Josef
AU - de Lemos, James A
AU - Ballantyne, Christie M.
N1 - Funding Information:
The Atherosclerosis Risk in Communities study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract nos. HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, and HHSN268201700004I. Dr. Selvin was supported by R01-DK089174. Dr. Ballantyne was supported by R01-HL134320. Drs. Nambi, Hoogeveen, and Ballantyne have a provisional patent (patent no. 61721475) titled “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche. Dr. Nambi has received a grant from Roche; and compensation for event adjudication from Siemens. Dr. Virani has received research grants from the American Heart Association, American Diabetes Association, and United States Department of Veterans Affairs; honoraria from the American College of Cardiology and the National Lipid Association; and has been on the steering committee for PALM Registry at Duke University. Dr. Hoogeveen has received a research grant from Denka Seiken. Dr. De Lemos has received grants from Roche Diagnostics and Abbot Diagnostics; has served as a consultant for Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, DSMB Novo Nordisc, Amgen, and Regeneron; and has been on the steering committee for Amgen. Dr. Ballantyne has received research support from Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Regeneron, Roche, Sanofi, and Takeda.
Publisher Copyright:
© 2018 American College of Cardiology Foundation
PY - 2018/6/5
Y1 - 2018/6/5
N2 - Background: Current prevention guidelines recommend using the Pooled Cohort Equation (PCE) for 10-year atherosclerotic cardiovascular disease (CVD) risk assessment. However, the PCE has serious limitations in older adults: it excludes heart failure (HF) hospitalization, estimates 10-year risk, which may not be the most relevant time frame, and is not indicated for individuals age >79 years. Objectives: This study sought to determine whether adding biomarkers to PCE variables improves global CVD (coronary heart disease, stroke, and HF) risk prediction in older adults over a shorter time period. Methods: Atherosclerosis Risk in Communities study participants without prevalent CVD including HF (n = 4,760; age 75.4 ± 5.1 years) were followed for incident global CVD events. Adding N-terminal pro–B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein to the PCE and a “lab model” with the biomarkers, age, race, and gender were assessed for prediction improvement. Area under the receiver operating characteristic curve (AUC) and net reclassification index (NRI) were calculated. Results: Over median follow-up of ∼4 years, incident HF was the leading CVD event (n = 193 vs. 118 coronary heart disease and 81 stroke events). Compared to the PCE, each biomarker improved risk prediction. The largest improvement in risk prediction metrics was with the addition of all 3 biomarkers (ΔAUC 0.103; continuous NRI 0.484). The lab model also performed better than the PCE model (ΔAUC 0.091, continuous NRI 0.355). Conclusions: Adding biomarkers to the PCE or a simpler “lab model” improves short-term global CVD risk prediction and may be useful to inform short-term preventive strategies in older adults.
AB - Background: Current prevention guidelines recommend using the Pooled Cohort Equation (PCE) for 10-year atherosclerotic cardiovascular disease (CVD) risk assessment. However, the PCE has serious limitations in older adults: it excludes heart failure (HF) hospitalization, estimates 10-year risk, which may not be the most relevant time frame, and is not indicated for individuals age >79 years. Objectives: This study sought to determine whether adding biomarkers to PCE variables improves global CVD (coronary heart disease, stroke, and HF) risk prediction in older adults over a shorter time period. Methods: Atherosclerosis Risk in Communities study participants without prevalent CVD including HF (n = 4,760; age 75.4 ± 5.1 years) were followed for incident global CVD events. Adding N-terminal pro–B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein to the PCE and a “lab model” with the biomarkers, age, race, and gender were assessed for prediction improvement. Area under the receiver operating characteristic curve (AUC) and net reclassification index (NRI) were calculated. Results: Over median follow-up of ∼4 years, incident HF was the leading CVD event (n = 193 vs. 118 coronary heart disease and 81 stroke events). Compared to the PCE, each biomarker improved risk prediction. The largest improvement in risk prediction metrics was with the addition of all 3 biomarkers (ΔAUC 0.103; continuous NRI 0.484). The lab model also performed better than the PCE model (ΔAUC 0.091, continuous NRI 0.355). Conclusions: Adding biomarkers to the PCE or a simpler “lab model” improves short-term global CVD risk prediction and may be useful to inform short-term preventive strategies in older adults.
KW - biomarkers
KW - cardiovascular disease
KW - elderly
KW - heart failure
KW - prevention
KW - risk assessment
UR - http://www.scopus.com/inward/record.url?scp=85047143216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047143216&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.02.050
DO - 10.1016/j.jacc.2018.02.050
M3 - Article
C2 - 29535064
AN - SCOPUS:85047143216
SN - 0735-1097
VL - 71
SP - 2527
EP - 2536
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 22
ER -